Thymoma: Clinical Trials

7 trials for Thymoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 unknown. 7 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 27Unknown 7

Follow Thymoma: new trials by email Literature Review of Thymoma trials Research Report on Thymoma

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
The Efficacy and Safety of Nanoparticle Albumin-bound (NAB)-Paclitaxel Plus Cisolation Versus CEP (Cisplatin, Epirubicin,Cyclophosphamide) in Induction Therapy for Thymoma: a Study for a Single-center Prospective Phase II Randomized Controlled Train.
NAB-Paclitaxel plus Cisplatin, Cisplatin plus Epirubicin plus Cyclophosphamide - Histological or Cytological Confirmed Stage Ⅲ and Ⅳa Thymoma
Phase 2UnknownPeng Liu502023-04-302023-04-18
Ramucirumab and Carbo-Paclitaxel for Untreated Thymic Carcinoma / B3 Thymoma With Carcinoma (RELEVENT)
Ramucirumab - Thymic Carcinoma, Thymoma
Phase 2UnknownClaudia Proto602018-11-012024-05-29
Hypofractionated Chemoradiotherapy and Thymosin α1 in Unresectable or Recurrent Thymic Epithelial Tumor
Thymosin a1, hypofractionated radiotherapy, concurrent chemoradiotherapy - Thymoma and Thymic Carcinoma
Phase 2UnknownSun Yat-sen University572018-08-132021-12-10
Selinexor in Patients With Advanced Thymoma and Thymic Carcinoma
Selinexor - Thymoma, Advanced Thymic Epithelial Tumour
Phase 2UnknownMorten Mau-Soerensen252017-10-122018-03-15
Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines (Style Trial)
Sunitinib - Type B3 Thymoma, Thymic Carcinoma
Phase 2UnknownFondazione IRCCS Istituto Nazionale dei Tumori, Milano562017-03-022021-06-09
Abscopal Effect of Radiotherapy in Combination With rhGM-CSF for Advanced Thymic Epithelial Tumours
Radiotherapy Combined with GM-CSF - Thymoma
Phase 2UnknownShanghai Cancer Hospital, China602016-01-012022-06-07
Pembrolizumab and Epacadostat in Patients With Thymic Carcinoma
Pembrolizumab, Epacadostat - Thymic Carcinoma, Thymus Neoplasms
Phase 2UnknownGeorgetown University452015-03-012019-12-13

Narrower conditions

Neoplasm Metastasis (1)  ·  Thymus Neoplasms (1)

Broader conditions

Hemic and Lymphatic Diseases (7)  ·  Lymphatic Diseases (7)  ·  Neoplasms (7)  ·  Neoplasms by Histologic Type (7)  ·  Neoplasms by Site (7)  ·  Neoplasms, Complex and Mixed (7)  ·  Thoracic Neoplasms (7)  ·  Thymus Neoplasms (6)  ·  Neoplastic Processes (1)  ·  Pathologic Processes (1)  ·  Pathological Conditions, Signs and Symptoms (1)

Interventions

130-nm albumin-bound paclitaxel (1)  ·  Carboplatin (1)  ·  Chemoradiotherapy (1)  ·  Cisplatin (1)  ·  Cyclophosphamide (1)  ·  Epirubicin (1)  ·  Granulocyte-Macrophage Colony-Stimulating Factor (1)  ·  Paclitaxel (1)  ·  Radiation Dose Hypofractionation (1)  ·  Ramucirumab (1)  ·  Sunitinib (1)  ·  epacadostat (1)  ·  pembrolizumab (1)  ·  selinexor (1)

Sponsors

Claudia Proto (1)  ·  Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (1)  ·  Georgetown University (1)  ·  Morten Mau-Soerensen (1)  ·  Peng Liu (1)  ·  Shanghai Cancer Hospital, China (1)  ·  Sun Yat-sen University (1)

Countries

China (3)  ·  Italy (2)  ·  Denmark (1)  ·  France (1)  ·  United States (1)

Top investigators

Giuseppe Giaccone, MD PhD (1)  ·  Hui Liu, Professor (1)  ·  Marina Chiara Garassino, MD (1)  ·  Marina Garassino, MD (1)  ·  Morten Mau-Soerensen, MD, PhD (1)

Results publications

PMID 10555755, PMID 11123390, PMID 12712448, PMID 14963856, PMID 15201427, PMID 15725919, PMID 17570676, PMID 18268188, PMID 19220526, PMID 19461405, PMID 21502559, PMID 25146529, PMID 25202099, PMID 25396308, PMID 25403584, PMID 25411417, PMID 27844328, PMID 28759346, PMID 29395863, PMID 34622229, PMID 8637524

NIH funding

2017 (1)